Tekmira Announces Election of Directors

Tekmira Announces Election of Directors

VANCOUVER, British Columbia, May 17, 2013 (GLOBE NEWSWIRE) -- Tekmira
Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of
RNA interference (RNAi) therapeutics, announced that the nominees listed in
the management proxy circular for the 2013 Annual and Special Meeting of
Shareholders were elected as directors of Tekmira at the annual meeting held
on May 14, 2013 in Vancouver. Detailed results of the vote for the election of
directors are set out below:

Nominee           Votes For % For  Votes Withheld % Withheld
Michael Abrams    1,944,876 99.25% 14,740         0.75%
Kenneth Galbraith 1,945,046 99.26% 14,570         0.74%
Don Jewell        1,945,116 99.26% 14,500         0.74%
Frank Karbe       1,942,816 99.14% 16,800         0.86%
Daniel Kisner     1,943,276 99.17% 16,340         0.83%
Mark J. Murray    1,942,146 99.11% 17,470         0.89%

About Tekmira

Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on
advancing novel RNAi therapeutics and providing its leading lipid nanoparticle
delivery technology to pharmaceutical partners. Tekmira has been working in
the field of nucleic acid delivery for over a decade and has broad
intellectual property covering LNPs. Further information about Tekmira can be
found at www.tekmirapharm.com. Tekmira is based in Vancouver, B.C.

CONTACT: Investors
         Jodi Regts
         Director, Investor Relations
         Phone: 604-419-3234
         Email: jregts@tekmirapharm.com
         David Ryan
         Longview Communications Inc.
         Phone: 416-649-8007
         Email: dryan@longviewcomms.ca

Tekmira Pharmaceuticals Logo
Press spacebar to pause and continue. Press esc to stop.